Literature DB >> 11714865

Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos.

D Dai1, J Tang, R Rose, E Hodgson, R J Bienstock, H W Mohrenweiser, J A Goldstein.   

Abstract

CYP3A4 is the most abundant isoform of cytochrome P450 (CYP) in adult human liver. It metabolizes numerous clinically, physiologically, and toxicologically important compounds. The expression of CYP3A4 varies 40-fold in individual human livers, and metabolism of CYP3A4 substrates varies at least 10-fold in vivo. Single nucleotide polymorphisms (SNPs) in CYP3A4 were identified by direct sequencing of genomic DNA in 72 individuals from three different ethnic groups, including Caucasians, Blacks (African-Americans and African pygmies), and Asians. A total of 28 SNPs were identified, including five which produced coding changes M445T (CYP3A4*3), R162Q (CYP3A4*15), F189S (CYP3A4*17), L293P (CYP3A4*18), and P467S (CYP3A4*19). The latter four represent new alleic variants. Racial variability was observed for the frequency of individual SNPs. CYP3A R162Q was identified only in Black populations with an allelic frequency of 4%. CYP3A4 F189S and CYP3A4 M445T were identified in Caucasians with allelic frequencies 2% and 4%, respectively. L293P and P467S were only observed in Asians at allelic frequencies of 2%. The cDNAs for the F189S, L293P, M445T, and P467S mutant alleles were constructed by site-directed mutagenesis and expressed in an Escherichia coli expression system. Testosterone and the insecticide chlorpyrifos were used to assess the catalytic activities of the most common CYP3A4 allele (CYP3A4*1) and its allelic variants. CYP3A4 F189S exhibited lower turnover numbers for testosterone and chlorpyrifos, while CYP3A4 L293P had higher turnover numbers for both substrates. The turnover numbers of the CYP3A4 M445T and P467S alleles to metabolize these compounds were not significantly different from those of wild-type CYP3A4.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11714865

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  67 in total

Review 1.  Role of pharmacogenomics in individualising treatment with SSRIs.

Authors:  Dalu Mancama; Robert W Kerwin
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

2.  Cytochrome P450-specific human PBPK/PD models for the organophosphorus pesticides: chlorpyrifos and parathion.

Authors:  Robert J Foxenberg; Corie A Ellison; James B Knaak; Changxing Ma; James R Olson
Journal:  Toxicology       Date:  2011-04-13       Impact factor: 4.221

Review 3.  Cytochrome P450 3A and their regulation.

Authors:  Oliver Burk; Leszek Wojnowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-21       Impact factor: 3.000

4.  CYP3A5 phenotype-genotype correlations in a British population.

Authors:  Barry P King; Julian B S Leathart; Elaine Mutch; Faith M Williams; Ann K Daly
Journal:  Br J Clin Pharmacol       Date:  2003-06       Impact factor: 4.335

5.  Urinary biomarkers of flame retardant exposure among collegiate U.S. gymnasts.

Authors:  Courtney C Carignan; Mingliang Fang; Heather M Stapleton; Wendy Heiger-Bernays; Michael D McClean; Thomas F Webster
Journal:  Environ Int       Date:  2016-07-06       Impact factor: 9.621

Review 6.  Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2021-01-18       Impact factor: 5.153

7.  CYP3A phenotypes and genotypes in North Indians.

Authors:  Naushad Rais; Yogesh K Chawla; Krishan K Kohli
Journal:  Eur J Clin Pharmacol       Date:  2006-04-21       Impact factor: 2.953

Review 8.  Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.

Authors:  Ron H N van Schaik
Journal:  Invest New Drugs       Date:  2005-12       Impact factor: 3.850

Review 9.  Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism.

Authors:  Bertrand Rochat
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 10.  Pharmacogenomics in colorectal cancer: the first step for individualized-therapy.

Authors:  Eva Bandrés; Ruth Zárate; Natalia Ramirez; Ana Abajo; Nerea Bitarte; Jesus Garíia-Foncillas
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.